AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie immunology Portfolio — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2025
30,406
Period ended Dec 31, 2025
Change on a year earlier
+14.0%
26,682 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Immunology Portfolio — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30,406 | +14.0% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 26,682 | +2.1% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 26,136 | -9.6% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 28,924 | +14.4% | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 25,284 | +14.1% | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 22,153 | +13.2% | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 19,571 | -1.8% | Form 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗ |
| FY2018 | Dec 31, 2018 | 19,936 | – | Form 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗ |
Breakdown
What makes up immunology portfolio — worldwide net revenues ($m)
- Immunology Portfolio — U.S. net revenues ($M)24,204 · FY2025
- Immunology Portfolio — International net revenues ($M)6,202 · FY2025
- Immunology Portfolio — Worldwide reported growth YoY (%)14.0% · FY2025
- Immunology Portfolio — Worldwide operational (constant-currency) growth YoY (%)13.9% · FY2025
- Skyrizi (risankizumab) — Worldwide net revenues ($M)17,562 · FY2025
- Rinvoq (upadacitinib) — Worldwide net revenues ($M)8,304 · FY2025
- Humira (adalimumab) — Worldwide net revenues ($M)4,540 · FY2025
Cite this data
StockData. (2026). AbbVie Immunology Portfolio — Worldwide net revenues ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta_imm_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.